The relationship between tissue inhibitor metalloproteinase-1 with colorectal cancer and tissue inhibitor metalloproteinase-1 as a predictor of colorectal cancer

I Gusti Agung Gede Darma Putra Suryapranata; I Made Mulyawan; Tjokorda Gde Bagus Mahadewa

doi:10.53730/ijhs.v6nS7.13617

Authors

I Gusti Agung Gede Darma Putra Suryapranata
gungjodxt@gmail.com
Resident at Department of General Surgery, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
I Made Mulyawan Division of Digestive, Department of General Surgery, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
Tjokorda Gde Bagus Mahadewa Division of Neurospine, Department of Neurosurgery, Faculty of Medicine, Udayana University, Prof Dr. IGNG Ngoerah General Hospital Denpasar, Bali, Indonesia, 80114

Keywords:

colorectal cancer, TIMP-1, MMP1, MMPs, Colorectal polyps

Abstract

Colorectal cancer is reported as the third most common case worldwide in men and accounts for 10% of all cancers. Matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases that affect the degradation and remodeling of extracellular components and contribute to the three Hallmarks of cancer. TIMP-1 is an endogenous MMP inhibitor with multiple functions related to the tumor microenvironment and colorectal cancer development. This study used a prospective cohort study design to prove that colorectal mucosa with high TIMP-1 expression is a prognostic factor in the incidence of colorectal cancer compared to normal/low TIMP values. This study involved 53 samples consisting of 27 polyp patients and 26 colorectal cancer patients. The bivariate analysis results showed a significant difference between TIMP-1 levels in cancer patients and colorectal polyps (p<0.001; 95%CI: 33.65-67.31). The cut-off value of 66.50 obtained a sensitivity value of 80.8% and a specificity value of 77.8% (p<0.001). Spearman rho correlation test found a significant positive correlation between TIMP-1 levels and cases of colorectal cancer (p<0.001) of 0.680. This study shows a significant relationship between TIMP-1 levels and colorectal cancer, where TIMP-1 is a good predictor of colorectal cancer incidence.

Downloads

Download data is not yet available.

References

Batra, J., Robinson, J., Soares, A.S., Fields, A.P., Radisky, D.C. and Radisky, E.S. (2012) 'Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.', The Journal of biological chemistry, 287(19), pp. 15935–15946. Available at: https://doi.org/10.1074/jbc.M112.341156.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) ‘Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, CA: A Cancer Journal for Clinicians, 68(6), pp. 394–424. Available at: https://doi.org/10.3322/caac.21492.

Granados-Romero, J.J., Valderrama-Treviño, A.I., Contreras-Flores, E.H., Barrera-Mera, B., Herrera Enríquez, M., Uriarte-Ruíz, K., Ceballos-Villalba, J.C., Estrada-Mata, A.G., Alvarado Rodríguez, C. and Arauz-Peña, G. (2017) ‘Colorectal cancer: a review’, International Journal of Research in Medical Sciences, 5(11), p. 4667. Available at: https://doi.org/10.18203/2320-6012.ijrms20174914.

Heitman, S.J., Ronksley, P.E., Hilsden, R.J., Manns, B.J., Rostom, A. and Hemmelgarn, B.R. (2009) ‘Prevalence of Adenomas and Colorectal Cancer in Average Risk Individuals: A Systematic Review and Meta-analysis’, Clinical Gastroenterology and Hepatology, 7(12), pp. 1272–1278. Available at: https://doi.org/10.1016/j.cgh.2009.05.032.

Holten-Andersen, M., Nielsen, H., Sørensen, S. and Al., E. (2006) ‘Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer’, Eur J Cancer, 42(12), pp. 1889–96.

Ishida, H., Murata, N., Hayashi, Y. and Al., E. (2003) ‘Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.’, Surg Today, 33, pp. 885–92.

Jan, S., Kimman, M., Kingston, D. and Woodward, M. (2012) 'The socioeconomic burden of cancer in member countries of the association of southeast Asian nations (ASEAN) - Stakeholder meeting report', Asian Pacific Journal of Cancer Prevention, 13(2), pp. 407–409. Available at: https://doi.org/10.7314/APJCP.2012.13.2.407.

Kostourou, V., Lechertier, T., Reynolds, L.E., Lees, D.M., Baker, M., Jones, D.T., Tavora, B., Ramjaun, A.R., Birdsey, G.M., Robinson, S.D., Parsons, M., Randi, A.M., Hart, I.R. and Hodivala-Dilke, K. (2013) ‘FAK-heterozygous mice display enhanced tumour angiogenesis.’, Nature communications, 4, p. 2020. Available at: https://doi.org/10.1038/ncomms3020.

Meng, C., Yin, X., Liu, J., Tang, K., Tang, H. and Liao, J. (2018) 'TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis, PLoS ONE, 13(11), pp. 1–15. Available at: https://doi.org/10.1371/journal.pone.0207039.

Min, B.S., Kim, N.K., Jeong, H.C. and Chung, H.C. (2012) ‘High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection’, Oncology Letters, 4(1), pp. 123–130. Available at: https://doi.org/10.3892/ol.2012.691.

Møller Sørensen, N., Vejgaard Sørensen, I., Ørnbjerg Wurtz, S., School, A.S., Dowell, B., Davis, G., Jarle Christensen, I., Jørgen Nielsen, H. and Brünner, N. (2008) 'Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment', Scandinavian Journal of Gastroenterology, 43(7), pp. 774–786. Available at: https://doi.org/10.1080/00365520701878163.

Niewiarowska, K., Pryczynicz, A., Dymicka-Piekarska, V., Gryko, M., Cepowicz, D., Famulski, W., Kemona, A. and Guzińska-Ustymowicz, K. (2014) 'Diagnostic significance of TIMP-1 level in serum and its immunohistochemical expression in colorectal cancer patients, Polish Journal of Pathology, 65(4), pp. 296–304. Available at: https://doi.org/10.5114/pjp.2014.48191.

Oudart, J.-B., Doué, M., Vautrin, A., Brassart, B., Sellier, C., Dupont-Deshorgue, A., Monboisse, J.-C., Maquart, F.-X., Brassart-Pasco, S. and Ramont, L. (2016) ‘The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.’, Oncotarget, 7(2), pp. 1516–1528. Available at: https://doi.org/10.18632/oncotarget.6399.

Song, G., Xu, S., Zhang, H., Wang, Y., Xiao, C., Jiang, T., Wu, L., Zhang, T., Sun, X., Zhong, L., Zhou, C., Wang, Z., Peng, Z., Chen, J. and Wang, X. (2016) ‘TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway’, Journal of Experimental & Clinical Cancer Research, 35(1), p. 148. Available at: https://doi.org/10.1186/s13046-016-0427-7.

Sørensen, N.M., Byström, P., Christensen, I.J., Berglund, Å., Nielsen, H.J., Brünner, N. and Glimelius, B. (2007) 'TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid, Clinical Cancer Research, 13(14), pp. 4117–4122. Available at: https://doi.org/10.1158/1078-0432.CCR-07-0186.

Vočka, M., Langer, D., Fryba, V., Petrtyl, J., Hanus, T., Kalousova, M., Zima, T. and Petruzelka, L. (2019) ‘Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer’, International Journal of Biological Markers, 34(3), pp. 292–301. Available at: https://doi.org/10.1177/1724600819866202.

Waas, E., Hendriks, T., Lomme, R. and T., W. (2005) ‘Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.’, Dis Colon Rectum, 48, pp. 700–10.